Corcept Therapeutics Incorporated (CORT) vs ImmunityBio, Inc. (IBRX)
- Corcept Therapeutics Incorporated CORT 110.16 −2.83%
- ImmunityBio, Inc. IBRX 9.18 −8.20%
Corcept Therapeutics Incorporated and ImmunityBio, Inc. are both Biotechnology companies. Corcept Therapeutics Incorporated is the larger, with a market value of $12.3B against $10.6B — 1.2× the size. ImmunityBio, Inc. has negative trailing earnings, so its P/E is not meaningful; Corcept Therapeutics Incorporated trades at 212×. ImmunityBio, Inc. grew revenue faster over the last twelve months: 192.9% against 16.0%. Corcept Therapeutics Incorporated has the higher net margin (6.53% vs −598.6%) and the higher return on invested capital (1.01% vs 0.00%). Across the 18 metrics below, Corcept Therapeutics Incorporated leads on 10 and ImmunityBio, Inc. on 8.
Valuation
Profitability
| Metric | CORT | IBRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 98.30% | 99.34% | 65.16% |
| Operating margin | 0.77% | (151.88%) | 0.00% |
| Net margin | 6.53% | (598.56%) | 0.00% |
| Free cash flow margin | 12.87% | (173.76%) | 0.00% |
| Return on equity | 8.08% | 122.85% | (56.36%) |
| Return on assets | 6.41% | (192.58%) | (48.04%) |
| Return on invested capital | 1.01% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack